Table 2 Characteristics, comorbidities, risk factors, symptoms, and vital signs
From: Legionella pneumonia in the Niagara Region, Ontario, Canada: a case series
Variable | Value |
|---|---|
Age, years, median (IQR) | 57 (47–66) |
Male sex, n (%) | 8 (57) |
Known comorbidities/risk factors, n (%) | |
Hypertension | 9 (64) |
Dyslipidemia | 7 (50) |
Diabetes | 4 (29) |
Coronary artery disease | 3 (21) |
Chronic lung disease | 2 (14) |
Chronic renal insufficiency | 4 (29) |
Immunosuppression | 2 (14) |
Cigarette smoking | 10 (71) |
Cannabis use | 3 (21) |
Symptoms, n (%) | |
Productive cough | 7 (50) |
Nonproductive cough | 5 (36) |
Shortness of breath | 12 (86) |
Pleuritic chest pain | 3 (21) |
Nonpleuritic chest pain | 2 (14) |
Diarrhea | 4 (29) |
Nausea/vomiting | 3 (21) |
Abdominal pain | 4 (29) |
Confusion/altered level of consciousness | 7 (50) |
Headache | 3 (21) |
Fatigue | 4 (21) |
Rigors | 7 (50) |
Myalgias | 4 (29) |
Vital signs at triage, n (%) | |
Heart rate >90 beats per minute | 10 (71) |
Respiratory rate >20 breaths per minute | 12 (93) |
Systolic blood pressure <90 mmHg | 1 (7) |
Temperature <36 °C or >38 °C | 10 (71) |
Laboratory values (normal range), mean ± SD | |
Leukocytes (4.0–11.0), ×109/L | 14.9 ± 4.9 |
Creatinine (46–92), μmol/L | 286 ± 460 |
Sodium (135–145), mmol/L | 133 ± 4 |
Phosphate (0.8–1.45), mmol/L | 1.48 ± 1.98 |
Creatine kinase (40–200), U/L | 1914 ± 2728 |
Bilirubin (3–22), μmol/L | 13 ± 11 |
Aspartate aminotransferase (10–40), U/L | 77 ± 63 |
Alanine aminotransferase (5–68), U/L | 54 ± 27 |
Alkaline phosphatase (50–135), U/L | 90 ± 31 |
Troponin (<0.045), μg/L | 0.66 ± 1.43 |
Lactate (0.4–2.1), mmol/L | 2.3 ± 1.3 |
Arterial pH (7.35–7.45) | 7.32 ± 0.14 |
Distribution of infiltrates on initial chest x-ray, n (%) | |
Unilateral | 9 (64) |
Bilateral | 5 (36) |